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Abstract
Background: Glaucoma will undoubtedly impact on a person’s ability to function as they go about their day-to-
day life. The purpose of this study is to investigate the amount of published knowledge in quality of life (QoL) and
visual disability studies for glaucoma, and make comparisons with similar research in other chronic conditions.
Methods: A systematic literature search of the Global Health, EMBASE Psychiatry and MEDLINE databases. Title
searches for glaucoma and six other example chronic diseases were entered alongside a selection of keywords
chosen to capture studies focusing on QoL and everyday task ability. These results were further filtered during a
manual search of resulting abstracts. Outcomes were the number of publications per year for each disease, number
relating to QoL and type of glaucoma QoL research.
Results: Fifteen years ago there were no published studies relating to the impact of glaucoma on QoL but by
2009 this had risen to 1.2% of all glaucoma articles. The number of papers relating to QoL as a proportion of all
papers in glaucoma in the past 10 years (0.6%) is smaller than for AMD and some other disabling chronic diseases.
Most QoL studies in glaucoma (82%) involve questionnaires.
Conclusion: QoL studies in glaucoma are increasing in number but represent a tiny minority of the total
publications in glaucoma research. There are fewer QoL articles in glaucoma compared to some other disabling
chronic conditions. The majority of QoL articles in glaucoma research use questionnaires; performance-based
measures of visual disability may offer an additional method of determining how the disease impacts on QoL.
Why study quality of life and disability in
glaucoma?
Definitions of visual impairment centre largely on the
application of numerical values to classify disease state
and pay less attention to what this means in terms of
the individual and the types of disability they may face
as a result of visual loss. For instance, whilst clinical
measures of visual function such as visual fields facilitate
the monitoring of disease severity in glaucoma, they
offer less insight into the perceived or actual impact of
the disease on the individual as they go about everyday
tasks. Yet, this information will be highly valued by the
patient: How will the disease impact on their quality of
life? How will their visual loss affect them psychologi-
cally? Will they still be able to read or drive? Will they
be able to recognise their loved ones? The reality appears
to be that decreased visual functioning can have a wide
number of disabling consequences on an individual’s
daily life, including increased likelihood of injury from
falls or automobile accidents [1-3] and a decreased abil-
ity to carry out activities of daily living [4-7], which can
in turn lead to reduced confidence in or even avoidance
of activities the patient once deemed important and
pleasurable [8,9]. Since quality of life (QoL) - the sense
of personal satisfaction with the conditions in which
one lives - is likely intertwined with how well the indivi-
dual is able to carry out the activities of daily living that
are most important to them, the need for a better
understanding into the types of visual disability faced by
individuals with glaucoma is glaring.
Establishing how the disease is likely to affect QoL is
not simply a task of using clinical measures of visual
function alone. For example, each patient is likely to
present a different pattern of impairment (visual disabil-
ity) depending on the combination of individual charac-
teristics of the disorder (such as contrast sensitivity,
visual field defect severity, colour vision deficits) that
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factors, personality characteristics, coping strategies, the
value placed on particular tasks and other factors will
also influence how the disease will impact on that indi-
vidual’s daily life [10,11]. Thus, only by direct investiga-
tion into perceived and measured problems experienced
by visually impaired individuals can informed insight be
gained into the types of disability experienced in every-
day life. This information is invaluable, since it offers a
means for the clinician to inform newly diagnosed indi-
viduals with regards to future changes to their lives and
possible strategies that they could employ to maximise
their independence and increase their QoL.
Glaucoma is a leading cause of irreversible vision
impairment with the number affected expected to
increase substantially in the future due to the aging of
the population [12]. Insight into how glaucoma affects
QoL might offer a means of developing treatment stra-
tegies tailored towards the individual’s needs. QoL also
has health economic implications; more precise knowl-
edge of the impact on QoL will help, for example, deter-
mine the level of disease at which the benefit of
screening for the disease outweighs costs [13]. It has
also been shown that good vision is valued much more
than many physicians realise [14] and that ophthalmolo-
gists often underestimate the impact of the disorder on
the patient’s QoL [15]. The development of methods for
investigating the functional ability and QoL of indivi-
duals with glaucoma is therefore vital for a better under-
standing of the condition for the ophthalmologist, the
patient and for an economic rationale for how to deal
with the condition. Research of this type is starting to
gather momentum in the literature, and has been
recently reviewed [16,17].
This study has three aims related to the published
research activity that has examined the impact of glau-
coma on disability and QoL to date. First, the study
aims to examine the hypothesis that publications, as a
surrogate of research activity in this area, are increasing
in number. Second, the study seeks to investigate the
hypothesis that this level of research activity in this area
is equivalent to some other example chronic conditions
including age-related macular degeneration (AMD).
Third, the study considers the hypothesis that the meth-
ods typically used in this type of research are reliant on
questionnaires and self report, leading to discussion on
the alternative approach of performance-based measures
which more directly assess patient functioning.
Literature search strategy
A systematic literature search was conducted of the
MEDLINE, EMBASE Psychiatry and Global Health data-
bases using the Ovid search platform on the 16th March
2010 and included publications indexed up until the end
of December 2009. Title searches were conducted for
seven example chronic conditions (glaucoma, AMD,
Type 2 Diabetes, rheumatoid arthritis, hearing impair-
ment, Parkinson’s Disease, Multiple Sclerosis) using the
key words displayed in Table 1 over a ten year period
(1999-2009). The search was extended to 20 years
(1989-2009) for the purpose of examining the trend
relating to glaucoma-related publications as a surrogate
measure of research activity trends in this area. The
results for each search were combined with the results
from an abstract search using the following ‘quality of
life’ key words or phrases: “quality of life”, “functional
consequences”, “performance”, “real world”, “functional
ability”, “everyday”, “daily living”, “daily life”, “beha-
viour”, “behavior”, “activities of daily living”, “indepen-
dent living”. Results were restricted to those papers
which contained one of the disease key words and at
least one of the QoL keywords. There were no language
or country restrictions and results were limited to a
human population. Review articles and reference sec-
tions of key papers were carefully read to look for any
other relevant papers which may not have been indexed
in these databases.
Keywords and phrases were chosen in an attempt to
include as many relevant papers as possible, but their
possible ambiguity and constraints relating to the search
platform meant that a large number of irrelevant papers
would also need to be excluded. A careful manual
search of the abstracts resulting from the search was
subsequently conducted. In order to be included in the
final results the paper had to be a systematic research
study with a strong emphasis on the impact of the dis-
ease on patient’s daily life (review articles were not
included). Papers where QoL was only used as a second-
ary measure or articles regarding ‘visual function’ as an
outcome of clinical measures were excluded. Another
exclusion criterion applied when the search terms
yielded papers focusing on the monetary costs of the
d i s e a s eo n ,f o re x a m p l e ,t h eU KN H So rh o s p i t a l s .
Those studies assessing QoL as an outcome of a drug
trial, surgery, rehabilitation method or other interven-
tion were not included in these search results, because
the number of QoL publications will be partially driven
by the demand for medical interventions for a particular
disorder. For instance, in order to judge the cost-effec-
tiveness of the development of a new drug, a measure-
ment of QoL is often needed to financially and ethically
justify the intervention. Since finances will be allocated
differently for different diseases, and demand for medi-
cal trials will vary, it was deemed inappropriate to
include these types of studies for the sake of a compari-
son-based paper.
The total number of all papers published for each of
the relevant years for each chronic disease (i.e. the
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the title) was also recorded. For example, this enabled
t h er e s u l t so ft h eg l a u c o m aQ O Ls t u d i e st ob ec o n s i d -
ered as a percentage of the total number of ‘glaucoma’
themed articles (i.e. featuring the word ‘glaucoma’ in the
title) for each year. Any difference in number of publica-
tions from year to year could thus most likely be attrib-
uted to interest in QoL instead of simply due to more
studies in general being published every year. In addi-
tion, abstracts (and full texts if necessary) for resulting
papers in the 20-year glaucoma search were examined
for information regarding the type of methods used to
investigate QoL in each study.
General trend in QoL publications in glaucoma
The initial literature search yielded a total of 294 papers
for QoL and glaucoma. Following a careful manual
search, 244 were excluded based on the additional filter-
ing criteria leaving a total of 51 suitable papers. Figure 1
illustrates an increase in the number of QoL studies
related to glaucoma between the early 1990s and the
present year; 15 years ago no published studies existed
on the subject, but since then a general increase has
occurred with the highest percentage of glaucoma stu-
dies relating to QoL being published in 2009 (1.2%; n =
8 of 660 - total number of glaucoma studies that year).
This obvious rise suggests that the relevance of studying
QoL in glaucoma is beginning to be understood. How-
ever, it is remarkable to note that these studies examin-
ing the life of the patient beyond the clinic are a very
small representation of the total number of glaucoma
papers published each year; despite there being a higher
proportion of glaucoma QoL themed papers in 2009
compared with earlier years, 1.2% is still undoubtedly
tiny. Of course the importance of other key areas of
research, such as the development of treatments and
clinical diagnostic measures cannot be underestimated.
However, this figure still seems anomalous for an area
of research which encompasses the core of disease,
which is how it actually manifests itself and impacts on
an individual.
QoL research in other chronic conditions
To gauge if QoL type research in glaucoma was
neglected more than in other chronic conditions, the
number of publications over the last 10 years for AMD,
hearing impairment, Parkinson’s Disease (PD), Multiple
Sclerosis (MS), Rheumatoid Arthritis and Type 2 Dia-
betes was examined. These were chosen not as an
exhaustive list of all chronic conditions, rather as merely
a set of comparative examples being analogous to glau-
coma: whilst they are not directly life-threatening, they
all lead to disability which is likely to have a detrimental
impact on QoL, typically worsening with time due to
the progressive and irreversible nature of the disease
[18-23]. From the example conditions assessed, those
with the highest percentage of QoL studies for the last
10 years were for PD (1.6%; n = 284 out of total of
17296 studies for PD), MS (1.4% n = 260 of 18458) and
AMD (1.1%; n = 60 of 5355). Hearing loss and rheuma-
toid arthritis had 0.7% (n = 44 of 6320) and 0.9% (n =
130 of 14412) respectively. Aside from Type 2 Diabetes
(0.5%; n = 146 of 31505), glaucoma had the lowest per-
centage of QoL themed studies over the 10 year period
(0.6%; n = 42 of 6966). Perhaps by 2009 the frequency
Table 1 Disease key words
Search
Number
Disease Key Words
1 “glaucoma” (1)
2 “age-related macular degeneration” or “AMD” or “age related macular disease” or “age related maculopathy” or “ARMD” or “macular
degeneration” or “macular disease”
3 “type 2 diabetes” or “type II diabetes” or “type two diabetes” or “diabetes mellitus”
4 “hearing impairment” or “hearing loss” or “loss of hearing” or “deafness”
5 “rheumatoid arthritis” or “rheumatic gout” or “rheumatoid disease”
6 “parkinson’s disease” or “parkinson disease”
7 “Multiple Sclerosis” or “MS” or “Acute Fulminating Sclerosis” or “Disseminated Sclerosis”
(1) Since synonyms for the disease all tend to contain the word ‘glaucoma’ (i.e. primary open angle glaucoma, normal-tension glaucoma, secondary glaucoma), it
was assumed that the term “glaucoma” alone would be sufficient to encapsulate all forms of the disease
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Figure 1 Number of QoL papers per year as a percentage of
all glaucoma articles.
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Page 3 of 6of QOL studies in glaucoma was more similar to other
chronic conditions but this represents only one year of
data. Thus, the results of this comparison indicate that
research in QoL in glaucoma has indeed been more
neglected on the whole compared to some other exam-
ple chronic conditions (Figure 2). In certain cases this is
perhaps not all that surprising; for instance since AMD
primarily affects central vision, its effects will be more
immediately obvious as a patient attempts to carry out
visually demanding tasks. Moreover, several factors may
contribute to the finding that some other example con-
ditions chosen for this study, such as PD (1.6% of total
studies were QoL) and MS (1.4%) also appear to have
more activity in this type of research. For example,
some medical specialties, like rheumatology, have a long
established history of assessment of QoL and policies to
promote the use of QoL research introduced by funding
bodies and professional organisations [24,25]. Moreover,
as a general observation, the amount of attention paid
to the impact of a disease on QoL may also be linked to
how ‘visible’ the disability is to both the patient and
those around them. This would be true of PD where the
‘visible’ symptoms also impact on the way the condition
is perceived to the further detriment of QoL of the suf-
ferer [26]. On the contrary, glaucoma patients them-
selves are often unaware of the full extent of their visual
loss and their symptoms are certainly less ‘noticeable’
compared to other conditions [27]. Likewise, individuals
with Type 2 Diabetes (which yielded the lowest number
of QoL studies as a proportion of all studies in this sam-
ple) tend to be asymptomatic [28] and is described as an
‘invisible’ disability [26]. The impact that diabetes and
glaucoma has on the individual’s daily life is conse-
quently harder for an outside observer to understand. It
follows that more research should perhaps be conducted
on the effect of these ‘invisible’ disabilities on QoL, a
notion that is being addressed in the literature [29-32].
Moreover, in glaucoma, perhaps more attention should
be paid to the research findings that have already chal-
lenged the belief that glaucoma is simply an insidious
process in which the symptoms do not appear until the
end stage of the disease [33,34].
Methods used in QoL assessment in glaucoma
Self-report questionnaires
Of the glaucoma-themed papers emerging from the lit-
erature search, 82% (n = 42) primarily involved the use
of questionnaires to investigate the impact of glaucoma
on the individual’s daily functioning. The majority of
these studies issued one or more established question-
naires with three main types; those measuring global
health (13 studies included at least one of this type of
questionnaire), those tailored towards vision-based out-
comes (n = 22), and those developed especially for indi-
viduals with glaucoma (n = 9). A further four studies
were dedicated to the development or validation of glau-
coma-specific QoL questionnaires. An alternative
method is the utility or time-trade-off approach, which
typically requires judgements such as whether the indi-
vidual would be willing to sacrifice a certain number of
years of their life in ‘exchange’ for good vision: four
papers included such a method. In addition, 11 studies
included a novel questionnaire specifically developed for
that study. Five studies involved the use of interview as
opposed to written questionnaires. References for all
studies identified in the glaucoma QoL search can be
found in “Additional file 1“.
Self-report questionnaires provide a valuable insight
into the patient’s personal experiences and how they per-
ceive the impact of the disease on their life outside the
clinic. It has been demonstrated that this important infor-
mation is not acquired within the time-constraints of
clinical appointments [35]. Individuals with glaucoma
have been shown to display a poor understanding of their
condition [36], and by asking them to comment on their
outcomes the patient is forced to consider the impact of
the disease on their own life. A collation of the data
would also be useful for devising more patient-centric
educational strategies. On the other hand, the usefulness
of questionnaires as a QoL tool may be compromised by
their subjective nature, as responses are of course difficult
to verify, and are subject to bias which can manifest in a
number of ways: for example, the knowledge that some-
thing is wrong with their vision has been shown to cause
the patient to exaggerate symptoms and difficulties [20]
or give responses they believe presents them in a socially
acceptable or more favourable light [37]. Moreover, peo-
ple with different expectations will self report in ques-
tionnaires that they have a different QoL even when they
have exactly the same clinical condition [38]. A patient’s
view of their QoL may also change over time due to the
manner in which they psychologically adapt to their
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Figure 2 Number of QoL studies as a percentage of all studies
for 7 chronic diseases over last 10 years.
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Page 4 of 6condition [39,40]. Nevertheless, since such questionnaires
provide the only feasible means of ascertaining the ways
in which the patient themselves feels glaucoma has
impacted on their QoL, the fact that so few studies have
been dedicated to the development and validation of
glaucoma-specific questionnaires is surprising.
Performance-based studies
An alternative approach for understanding visual disabil-
ity in glaucoma is to measure the patient’s actual perfor-
mance in surrogates of tasks they would encounter
every day. The results from the survey indicated fewer
studies (18% of studies [n = 9]) have taken this approach
in glaucoma research. In these studies, the tasks investi-
gated were: mobility performance in terms of ability to
navigate around an obstacle course (n = 2); driving
using simulations or direct on-road performance
(n = 2); reading ability (n = 2); postural sway and bal-
ance (n = 2) and eye-hand co-ordination (n = 1).
This apparent lack of performance based research in
glaucoma is surprising as, although the systematic con-
trol needed for this type of experiment probably places
limits on how realistic the study can be, there is some
evidence that task performance in the laboratory corre-
lates well with how individuals carry out the tasks in
their own home [41]. The performance-based method
also helps eliminate the types of biases which coincide
with the self-report method. Moreover, since glaucoma
is typically perceived as asymptomatic until a more
advanced stage, it is possible that performance-based
assessments could capture difficulties in activities that
the individual may not be sufficiently consciously aware
to be able to report them in a questionnaire [42]. The
development of objective measures could also potentially
offer clinicians a valuable patient-centred method to
monitor disease progression and to develop and evaluate
the effects of management strategies. However, perfor-
mance-based measures of visual disability are likely not
a sufficient substitute for questionnaires because they
don’t, for example, measure ‘feelings’, symptoms or well
being. Thus, it may be that disability should be mea-
sured using a combination of clinical, self-report and
performance based measures to get an overall picture of
t h ei m p a c to fg l a u c o m ao nt h ep a t i e n t ’s life. This
approach was recently taken in the Salisbury Eye Evalua-
tion (SEE) Project [43,44] where both patient percep-
tions of QoL using the NEI-VFQ-25 and their
performance in a number of daily tasks such as locating
objects and using the telephone were examined, and
related to the extent of visual loss.
Conclusions
The importance of QoL studies in glaucoma recently
appears to have been better recognised as the
proportion of papers published relating to QoL as a sur-
rogate measure of research activity in the area is
increasing. Nevertheless, QoL studies in glaucoma repre-
sent only a very small fraction of the total publications
in glaucoma research each year. Furthermore, there are
fewer QoL papers in glaucoma compared to QoL type
studies in some other disabling chronic conditions,
including AMD. The majority of those QoL studies pub-
lished in glaucoma research are based on self-report
questionnaires; despite limitations this method is the
best way of measuring the patient’s perspective on their
disease. Studies reliant on performance-based measures
of visual disability are rarer but offer an additional
method of increasing awareness of visual disability
caused by glaucoma. Further research in these areas
could prove invaluable for future management and reha-
bilitation in glaucoma. In turn this could help shift
emphasis from the clinic towards the individuals facing
the impact of visual loss on their daily lives.
Additional material
Additional file 1: References for papers identified in glaucoma QoL
search.
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